Pharmaceuticals, Biotechnology and Life Sciences
– Monotherapy Phase I dose escalation remains ongoing; BT5528 appears well-tolerated as dosing approaches clinically relevant levels – BT5528 is…
Bicycle is going to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer’s disease and…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class of…
– Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models – Early analysis of…
– Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors – Successfully…
Bicycle Therapeutics today announced two senior appointments to facilitateits expanding and advancing clinical pipeline.
Punit Upadhyaya, Ph.D., SeniorScientist at Bicycle, will present at the 6th Annual PeptidesCongress in London.
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…